Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Bipolar disorder stories

Nov 16, 2026

FDA approves at-home use of BioXcel's agitation drug Igalmi

The FDA approved at-home use of BioXcel Therapeutics' Igalmi (dexmedetomidine) for agitation associated with schizophrenia or bipolar disorder, expanding access beyond clinical settings.

Nov 16, 2026·2 sources
00

Top claims

  • ▪Schizophrenia causes delusions, hallucinations, and disorganized thinking, while bipolar disorder causes severe mood swings
  • ▪Agitation affects between 25% and 40% of patients diagnosed with schizophrenia or bipolar disorder, according to statements by Teva Pharmaceuticals
  • ▪BioXcel Therapeutics completed the sale of nearly all its assets, including Igalmi, to a unit of Israel-based Teva Pharmaceuticals last month

Topics

FDA drug approvalMental Health & WellbeingDrug Policy, Pricing & ApprovalPsychosis & schizophrenia spectrum

Related entities

IsraelSchizophrenia